{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028788","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.239177+00:00","generated_at":"2026-06-05T09:07:08.657357+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx Pharmaceuticals prices $1.5M public offering of 5M shares at $0.30 per share","bullets":["Underwritten public offering of 5,000,000 shares of common stock at $0.30/share, gross proceeds approx. $1.5 million.","EF Hutton LLC sole book-runner; underwriters have 45-day option for up to 750,000 additional shares.","Proceeds for working capital and general corporate purposes; may repay convertible note to Streeterville Capital.","Underwriter's warrant issued for up to 250,000 shares at $0.33/share, exercisable after 6 months for 5 years.","Offering closed Feb 28, 2024; 90-day lock-up for directors, officers, and company."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028788","json":"https://secwatch.observer/filing/0001104659-24-028788.json","markdown":"https://secwatch.observer/filing/0001104659-24-028788.md","text":"https://secwatch.observer/filing/0001104659-24-028788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/0001104659-24-028788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/tm247473d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:07:08.657357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"501997e0d410e3ff64580b89f385e48ff5d4c414","claim":"NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, NRx Pharmaceuticals, Inc. (the \" Company \") entered into an underwriting agreement (the \" Underwriting Agreement \") with EF Hutton LLC (the \" Representative \"), as the representative of the several underwriters named therein (the \" Underwriters \"), relating to an underwritten public offering (the \" Offering \") of 5,000,000 shares (the \" Shares \") of the Company’s common stock, par value $0.001 per share (\" Common Stock \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/0001104659-24-028788-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"EF Hutton LLC"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}